VITT is characterised by exposure to one of the aforementioned vaccines 4–30 days prior to presentation, followed by thrombosis, mild-to-severe thrombocytopenia, and a positive PF4-heparin enzyme-linked immunosorbent assay (ELISA). This evidence concerns the gene PF4 and Venous thrombosis.